Arcadia Biosciences

Arcadia Biosciences, Inc. is an agricultural biotechnology trait company. The Company develops a portfolio of yield and traits addressing multiple crops that supply the global food and feed markets. It has a pipeline of products in development incorporating its traits, including products that are in advanced stages of development or on the market. Its crop yield traits are utilized by its partners to develop higher yielding seeds for global crops, including wheat, rice, soybean, corn, and sugarcane, as well as for other crops, such as cotton, turf and trees. The Company's portfolio of agricultural productivity traits includes Nitrogen Use Efficiency (NUE), Water Use Efficiency (WUE), Drought Tolerance (DT), Salinity Tolerance (ST) and Herbicide Tolerance. It has presence in the United States, Africa, India, the United Arab Emirates, Belgium, France and Canada.
Company Growth (employees)
Type
Public
HQ
Davis, US
Size (employees)
57 (est)
Arcadia Biosciences is headquartered in Davis, US

Key People at Arcadia Biosciences

Vic Knauf

Vic Knauf

Chief Scientific Officer
Zhongjin Lu

Zhongjin Lu

Vice President of Product Development
Don Emlay

Don Emlay

Vice President of Regulatory Affairs

Arcadia Biosciences Office Locations

Arcadia Biosciences has an office in Davis
Davis, US (HQ)
105 202 Cousteau Pl

Arcadia Biosciences Data and Metrics

Arcadia Biosciences Financial Metrics

Arcadia Biosciences's revenue was reported to be $1 m in Q1, 2017
USD

Revenue (Q1, 2017)

1 m

EBIT (Q1, 2017)

(4 m)

Market capitalization (17-Aug-2017)

19.2 m

Cash (31-Mar-2017)

7.6 m
Arcadia Biosciences's current market capitalization is $19.2 m.
USDFY, 2015FY, 2016

Revenue

5.4 m3.2 m

Revenue growth, %

(41%)

R&D expense

9 m8.7 m

General and administrative expense

11.1 m12.3 m

Operating expense total

21 m21.8 m

EBIT

(15.6 m)(18.6 m)

EBIT margin, %

(287%)(584%)

Interest expense

(2.7 m)(1.3 m)

Pre tax profit

(19.6 m)

Income tax expense

(26 k)(25 k)

Net Income

(18 m)(19.6 m)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

815 k1.4 m1.8 m852 k721 k1.1 m1 m

R&D expense

1.8 m2.1 m3.2 m2.2 m2.2 m2.3 m1.8 m

General and administrative expense

2.6 m2.8 m2.8 m3.4 m2.8 m2.7 m3.1 m

Operating expense total

4.5 m4.9 m6 m5.6 m5 m4.9 m4.9 m

EBIT

(3.7 m)(3.5 m)(4.2 m)(4.9 m)(4.3 m)(3.9 m)(4 m)

EBIT margin, %

(455%)(248%)(232%)(579%)(595%)(365%)(389%)

Interest expense

(467 k)(775 k)(766 k)(327 k)(327 k)(331 k)(339 k)

Pre tax profit

(5.2 m)(4.5 m)(4.2 m)(4.2 m)

Income tax expense

(229 k)(90 k)97 k(6 k)(11 k)(7 k)(10 k)

Net Income

(5.2 m)(4.6 m)(4.2 m)
USDFY, 2015FY, 2016

Cash

24 m2 m

Accounts Receivable

706 k349 k

Inventories

692 k877 k

Current Assets

52 m52.2 m

PP&E

585 k508 k

Total Assets

74.2 m56.6 m

Accounts Payable

2.4 m2.4 m

Total Debt

49.9 m50.3 m

Current Liabilities

3.5 m3.1 m

Total Liabilities

34.4 m

Additional Paid-in Capital

172.2 m173.7 m

Retained Earnings

(131.9 m)(151.6 m)

Total Equity

40.2 m22.2 m

Debt to Equity Ratio

1.2 x2.3 x

Debt to Assets Ratio

0.7 x0.9 x

Financial Leverage

1.8 x2.5 x
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

11.3 m80 m63 m29.5 m27.4 m10.5 m7.6 m

Accounts Receivable

150 k145 k685 k587 k177 k97 k284 k

Current Assets

12.4 m81.6 m76.6 m52.5 m56.2 m55.7 m50.4 m

PP&E

663 k633 k597 k656 k636 k580 k486 k

Total Assets

19.4 m85 m80 m70.1 m65.7 m61.6 m52.6 m

Accounts Payable

3.4 m4.7 m4 m2.8 m2.6 m2.6 m2.2 m

Current Liabilities

12.1 m11.8 m10.9 m4.2 m4.1 m3.8 m5.2 m

Additional Paid-in Capital

27.9 m171.3 m171.9 m172.6 m172.9 m173.3 m174.1 m

Retained Earnings

(119.8 m)(123.5 m)(128.1 m)(137.1 m)(141.7 m)(145.8 m)(155.8 m)

Total Equity

(91.9 m)47.9 m43.8 m35.5 m31.3 m27.5 m18.4 m

Financial Leverage

-0.2 x1.8 x1.8 x2 x2.1 x2.2 x2.9 x
USDFY, 2015FY, 2016

Net Income

(18 m)(19.6 m)

Depreciation and Amortization

294 k304 k

Accounts Receivable

336 k357 k

Inventories

412 k582 k

Accounts Payable

125 k(19 k)

Cash From Operating Activities

(15.1 m)(17.1 m)

Purchases of PP&E

(151 k)(231 k)

Cash From Investing Activities

(46.4 m)(5.3 m)

Cash From Financing Activities

68.9 m396 k

Interest Paid

2.1 m1 m

Income Taxes Paid

149 k29 k
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(5.2 m)(4.6 m)(4.2 m)

Accounts Receivable

150 k145 k685 k587 k177 k97 k284 k

Accounts Payable

3.4 m4.7 m4 m2.8 m2.6 m2.6 m2.2 m
USDY, 2017

Revenue/Employee

17.9 k

Financial Leverage

2.9 x

Arcadia Biosciences Market Value History

Traffic Overview of Arcadia Biosciences

Arcadia Biosciences Company Life and Culture

You may also be interested in